{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:42:47Z","timestamp":1774453367460,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T00:00:00Z","timestamp":1434499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T00:00:00Z","timestamp":1434499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The purpose of this article is to disseminate the standard of antiemetic therapy for Japanese clinical oncologists. On the basis of the Appraisal of Guidelines for Research and Evaluation II instrument, which reflects evidence-based clinical practice guidelines, a working group of the Japanese Society of Clinical Oncology (JSCO) reviewed clinical practice guidelines for antiemesis and performed a systematic review of evidence-based domestic practice guidelines for antiemetic therapy in Japan. In addition, because health-insurance systems in Japan are different from those in other countries, a consensus was reached regarding standard treatments for chemotherapy that induce nausea and vomiting. Current evidence was collected by use of MEDLINE, from materials from meetings of the American Society of Clinical Oncology National Comprehensive Cancer Network, and from European Society of Medical Oncology\/Multinational Association of Supportive Care in Cancer guidelines for antiemesis. Initially, 21 clinical questions (CQ) were selected on the basis of CQs from other guidelines. Patients treated with highly emetic agents should receive a serotonin (5-hydroxytryptamine; 5HT<jats:sub>3<\/jats:sub>) receptor antagonist, dexamethasone, and a neurokinin 1 receptor antagonist. For patients with moderate emetic risk, 5HT<jats:sub>3<\/jats:sub> receptor antagonists and dexamethasone were recommended, whereas for those receiving chemotherapy with low emetic risk dexamethasone only is recommended. Patients receiving high-emetic-risk radiation therapy should also receive a 5HT<jats:sub>3<\/jats:sub> receptor antagonist. In this paper the 2010 JSCO clinical practice guidelines for antiemesis are presented in English; they reveal high concordance of Japanese medical circumstances with other antiemetic guidelines that are similarly based on evidence.<\/jats:p>","DOI":"10.1007\/s10147-015-0852-1","type":"journal-article","created":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T06:47:04Z","timestamp":1434437224000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary"],"prefix":"10.1007","volume":"21","author":[{"given":"Hideki","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Aiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Aogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Okita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuhei","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Akechi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Udagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Okawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Onozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Shima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohito","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Nishidate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,17]]},"reference":[{"key":"852_CR1","unstructured":"NCCN (2009) Clinical practice guidelines in oncology-antiemesis-ver. 4"},{"key":"852_CR2","unstructured":"MASCC\/ESMO-antiemetic guidelines (2008, 2010)"},{"key":"852_CR3","unstructured":"ASCO (2006) Guidelines for antiemetics in oncology: update"},{"key":"852_CR4","unstructured":"www.agreetrust.org\/resource-centre\/agree-ii\/. Accessed June 2009"},{"key":"852_CR5","unstructured":"The Cochrane Library (2009) issue 3"},{"key":"852_CR6","unstructured":"Kimura K, Yamada K, Uzuka Y et al (1982) Phase I study of N4-behenoyl-1-1-beta-d-arabinofuranosylcytosine and its phase II study in adult acute leukemia. Current chemotherapy and immunotherapy. In: Proceedings of the 12th International Congress of Chemotherapy, pp 1306\u20131308"},{"key":"852_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10637-006-9012-9","volume":"25","author":"T Yana","year":"2007","unstructured":"Yana T, Negoro S, Takada M et al (2007) Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 25:253\u2013258","journal-title":"Invest New Drugs"},{"key":"852_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/annonc\/mdj936","volume":"17","author":"F Roila","year":"2006","unstructured":"Roila F, Hesketh PJ, Herrstedt J et al (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20\u201328","journal-title":"Ann Oncol"},{"key":"852_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/annonc\/mdn105","volume":"19","author":"J Herrstedt","year":"2008","unstructured":"Herrstedt J, Rolia F (2008) Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophyraxis. Ann Oncol 19:110\u2013112","journal-title":"Ann Oncol"},{"key":"852_CR10","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1056\/NEJM200005253422102","volume":"342","author":"The Italian Group for Antiemetic Research","year":"2000","unstructured":"The Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554\u20131559","journal-title":"N Engl J Med"},{"key":"852_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","volume":"10","author":"M Saito","year":"2009","unstructured":"Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomized, comparative phase III trial. Lancet Oncol 10:115\u2013124","journal-title":"Lancet Oncol"},{"key":"852_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/BF00258206","volume":"7","author":"MS Aapro","year":"1981","unstructured":"Aapro MS, Alberts DS (1981) High-dose dexamethasone for prevention of cisplatin-induced vomiting. Cancer Chemother Pharmacol 7:11\u201314","journal-title":"Cancer Chemother Pharmacol"},{"key":"852_CR13","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1200\/JCO.2000.18.19.3409","volume":"18","author":"JP Ioannidis","year":"2000","unstructured":"Ioannidis JP, Hesketh PJ, Lau J (2000) Contribution of dexamethasone to control chemotherapy-induced nausea and vomiting; a meta-analysis of randomized evidence. J Clin Oncol 18:3409\u20133422","journal-title":"J Clin Oncol"},{"key":"852_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/annonc\/mdl347","volume":"18","author":"SM Grunberg","year":"2007","unstructured":"Grunberg SM (2007) Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol 18:233\u2013240","journal-title":"Ann Oncol"},{"key":"852_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/bjc.1997.341","volume":"76","author":"S Sekine","year":"1997","unstructured":"Sekine S, Nishiwaki Y, Kakinuma R et al (1997) Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis JCOG study 9413. Br J Cancer 76:90\u201392","journal-title":"Br J Cancer"},{"key":"852_CR16","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s00520-004-0629-y","volume":"12","author":"P Glare","year":"2004","unstructured":"Glare P, Pereira G, Kristjanson LJ et al (2004) Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer 12:432\u2013440","journal-title":"Support Care Cancer"},{"key":"852_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jpainsymman.2004.01.009","volume":"28","author":"E Bruera","year":"2004","unstructured":"Bruera E, Moyano JR, Sala R et al (2004) Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manage 28:381\u2013388","journal-title":"J Pain Symptom Manage"},{"key":"852_CR18","unstructured":"Cancer Care Ontario. The role of neurokinin-1 receptor antagonists in the prevention of emesis due to high-dose cisplatin. http:\/\/www.cancercare.on.ca\/pdf\/pebc12-4f.pdf. Accessed June 2009"},{"key":"852_CR19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2007.0004","volume":"5","author":"DS Ettinger","year":"2007","unstructured":"Ettinger DS, Bierman PJ, Bradbury B et al (2007) Antiemesis. J Natl Compr Canc Netw 5:12\u201333","journal-title":"J Natl Compr Canc Netw"},{"key":"852_CR20","doi-asserted-by":"crossref","unstructured":"Valle JW, Wasan HS, Palmer DD et al (2009) Gemcitabine with or without cisplatin in patients with advanced or metastatic biliary tract cancer (ABC): results of a multicenter randomized phase III trial (the UK ABC-02 trial). J Clin Oncol 27:15s (suppl; abstr 4503)","DOI":"10.1200\/jco.2009.27.15_suppl.4503"},{"key":"852_CR21","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1056\/NEJM198706043162302","volume":"316","author":"SD Williams","year":"1987","unstructured":"Williams SD, Birch R, Einhorn LH et al (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435\u20131440","journal-title":"N Engl J Med"},{"key":"852_CR22","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1056\/NEJM198212093072402","volume":"307","author":"GR Morrow","year":"1982","unstructured":"Morrow GR, Morrel C (1982) Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 307:1476\u20131480","journal-title":"N Engl J Med"},{"key":"852_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0885-3924(91)90011-R","volume":"6","author":"GR Morrow","year":"1991","unstructured":"Morrow GR, Lindke J, Black PM et al (1991) Predicting development of anticipatory nausea in cancer patients: prospective examination of right clinical characteristics. J Pain Symptom Manage 6:215\u2013223","journal-title":"J Pain Symptom Manage"},{"key":"852_CR24","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1002\/1097-0142(19881215)62:12<2607::AID-CNCR2820621226>3.0.CO;2-S","volume":"62","author":"MA Andrykowski","year":"1988","unstructured":"Andrykowski MA, Jacobsen PB, Marks E et al (1988) Prevalence, predictors, and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer. Cancer 62:2607\u20132613","journal-title":"Cancer"},{"key":"852_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000226675","volume":"46","author":"E Alba","year":"1989","unstructured":"Alba E, Bastus R, de Andres L et al (1989) Anticipatory nausea and vomiting: prevalence and predictors in chemotherapy patients. Oncology 46:26\u201330","journal-title":"Oncology"},{"key":"852_CR26","first-page":"585","volume":"68","author":"GR Morrow","year":"1982","unstructured":"Morrow GR (1982) Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 68:585\u2013588","journal-title":"J Natl Cancer Inst"},{"key":"852_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/00000421-199504000-00017","volume":"18","author":"IA Malik","year":"1995","unstructured":"Malik IA, Khan WA, Qazilbash M et al (1995) Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 18:170\u2013175","journal-title":"Am J Clin Oncol"},{"key":"852_CR28","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1200\/JCO.1993.11.7.1384","volume":"11","author":"D Razavi","year":"1993","unstructured":"Razavi D, Delvaux N, Farvacques C et al (1993) Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study of assessing the usefulness of alprazolam. J Clin Oncol 11:1384\u20131390","journal-title":"J Clin Oncol"},{"key":"852_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s005200050163","volume":"6","author":"PC Feyer","year":"1998","unstructured":"Feyer PC, Stewart AL, Titlbach OJ et al (1998) Aetiology and prevention of emesis induced by radiotherapy. Support Care Cancer 6:253\u2013260","journal-title":"Support Care Cancer"},{"key":"852_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/sj.bmt.1702479","volume":"26","author":"TR Spitzer","year":"2000","unstructured":"Spitzer TR, Friedman CJ, Bushnell W et al (2000) Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant 26:203\u2013210","journal-title":"Bone Marrow Transplant"},{"key":"852_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/annonc\/2.suppl_2.107","volume":"2","author":"M Tonato","year":"1991","unstructured":"Tonato M, Rolia F, Del Favero A et al (1991) Methodology of antiemetic trials. Ann Oncol 2:107\u2013114","journal-title":"Ann Oncol"},{"key":"852_CR32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.1987.5.1.141","volume":"5","author":"F Rolia","year":"1987","unstructured":"Rolia F, Tonato M, Basurto C et al (1987) Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 5:141\u2013149","journal-title":"J Clin Oncol"},{"key":"852_CR33","first-page":"796","volume":"309","author":"JR Sullivan","year":"1983","unstructured":"Sullivan JR, Leyden MJ, Bell R et al (1983) Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med 309:796","journal-title":"N Engl J Med"},{"key":"852_CR34","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00520-007-0338-4","volume":"16","author":"SB Hasler","year":"2008","unstructured":"Hasler SB, Hirt A, Luethy AR et al (2008) Safety of ondansetron loading doses in children with cancer. Support Care Cancer 16:469\u2013475","journal-title":"Support Care Cancer"},{"key":"852_CR35","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.arcmed.2008.04.007","volume":"39","author":"AC Sepulveda-Vildosola","year":"2008","unstructured":"Sepulveda-Vildosola AC, Betanzos-Cabrera Y, Lastiri GG et al (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 39:601\u2013606","journal-title":"Arch Med Res"},{"key":"852_CR36","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/pbc.21811","volume":"52","author":"L Gore","year":"2009","unstructured":"Gore L, Chawla S, Petrilli A et al (2009) Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 52:242\u2013247","journal-title":"Pediatr Blood Cancer"},{"key":"852_CR37","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1046\/j.1365-2036.1998.00410.x","volume":"12","author":"NJ Talley","year":"1998","unstructured":"Talley NJ, Meineche-Schmidt V, Pare P et al (1998) Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials. Aliment Pharmacol Ther 12:1055\u20131065","journal-title":"Aliment Pharmacol Ther"},{"key":"852_CR38","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1002\/1097-0142(20001201)89:11<2301::AID-CNCR19>3.0.CO;2-6","volume":"89","author":"A Giglio","year":"2000","unstructured":"Giglio A, Soares HP, Caparroz C et al (2000) Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer 89:2301\u20132308","journal-title":"Cancer"},{"key":"852_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0009-9236(03)00066-3","volume":"74","author":"JB McCrea","year":"2003","unstructured":"McCrea JB, Majumdar AK, Goldberg MR et al (2003) Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74:17\u201324","journal-title":"Clin Pharmacol Ther"},{"key":"852_CR40","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112\u20134119","journal-title":"J Clin Oncol"},{"key":"852_CR41","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1002\/cncr.11433","volume":"97","author":"S Poli-Bigelli","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3030\u20133038","journal-title":"Cancer"},{"key":"852_CR42","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00228-005-0907-8","volume":"61","author":"M Depre","year":"2005","unstructured":"Depre M, Van Hecken A, Oeyen M et al (2005) Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 61:341\u2013346","journal-title":"Eur J Clin Pharmacol"},{"key":"852_CR43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jpainsymman.2006.10.015","volume":"34","author":"SC Teunissen","year":"2007","unstructured":"Teunissen SC, Wesker W, Kruitwagen C et al (2007) Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 34:94\u2013104","journal-title":"J Pain Symptom Manage"},{"key":"852_CR44","first-page":"889","volume":"26","author":"VA Rhodes","year":"1999","unstructured":"Rhodes VA, McDaniel RW (1999) The index of nausea, vomiting, and retching: a new format of the index of nausea and vomiting. Oncol Nurs Forum 26:889\u2013894","journal-title":"Oncol Nurs Forum"},{"key":"852_CR45","first-page":"72","volume":"66","author":"GR Morrow","year":"1992","unstructured":"Morrow GR (1992) A patient report measure for the quantification of chemotherapy induced nausea and emesis: psychometric properties of the Morrow assessment of nausea and emesis (MANE). Br J Cancer 66:72\u201374","journal-title":"Br J Cancer"},{"key":"852_CR46","first-page":"72","volume":"66","author":"CM Lindley","year":"1992","unstructured":"Lindley CM, Hirsch JD, O\u2019Neill CV et al (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 66:72\u201374","journal-title":"Qual Life Res"},{"key":"852_CR47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.annonc.a058345","volume":"4","author":"C Ripamonti","year":"1993","unstructured":"Ripamonti C, De Conno F, Ventafridda V et al (1993) Management of bowel obstruction in advanced and terminal cancer patients. Ann Oncol 4:15\u201321","journal-title":"Ann Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-015-0852-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-015-0852-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-015-0852-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-015-0852-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T15:29:33Z","timestamp":1630596573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-015-0852-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,17]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s10147-015-0852-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,17]]},"assertion":[{"value":"7 May 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}